Selexis to Meet with Companies Interested in Mammalian Cell Line Development, Lead Identification for Therapeutic Drug Development and Solutions for Difficult-to-Express Proteins
Geneva, Switzerland (PRWEB) April 20, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today the Company’s Chief Scientific Officer, Pierre-Alain Girod, PhD, will be speaking on Fc Fusion Proteins at the 2011 ESACT Meeting on May 15, 2011, at the Hofburg Congress Center in Vienna.
Dr. Girod will be speaking in a workshop titled, “Fc Fusion Proteins: A Growing Class of Therapeutics” on Sunday, May 15, 14:00 – 15:45. Registration for the workshop is required.
The potential therapeutic value of many proteins—including enzymes, cell-surface receptors, cytokines and peptides—can be realized by fusing these proteins to the Fc region of human immunoglobulin G. Of the 30 MAb products approved as human therapeutics in the USA to date, 4 are Fc fusion proteins, and many more are in clinical testing. Considerations in fusion protein design and production will be presented.
Companies or individuals attending the conference can register for the EASCT meeting by visiting http://www.esact2011.com